Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

BACKGROUND COPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumulated about the prevention of acute exacerbations. METHODS In recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. Three key clinical questions developed using the PICO (population, intervention, comparator, and outcome) format addressed the prevention of acute exacerbations of COPD: nonpharmacologic therapies, inhaled therapies, and oral therapies. We used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion. RESULTS The AECOPD Guideline is unique not only for its topic, the prevention of acute exacerbations of COPD, but also for the first-in-kind partnership between two of the largest thoracic societies in North America. The CHEST Guidelines Oversight Committee in partnership with the CTS COPD Clinical Assembly launched this project with the objective that a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD would lead to a series of recommendations to assist clinicians in their management of the patient with COPD. CONCLUSIONS This guideline is unique because it provides an up-to-date, rigorous, evidence-based analysis of current randomized controlled trial data regarding the prevention of COPD exacerbations.

[1]  M. Petticrew,et al.  Developing and evaluating complex interventions: the new Medical Research Council guidance , 2008, BMJ : British Medical Journal.

[2]  M. Cazzola,et al.  Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. , 2011, Trends in pharmacological sciences.

[3]  L. Allegra,et al.  Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. , 1996, Respiration; international review of thoracic diseases.

[4]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[5]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.

[6]  M. Cazzola,et al.  An update on bronchodilators in Phase I and II clinical trials , 2012, Expert opinion on investigational drugs.

[7]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[8]  C. Cooper,et al.  The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.

[9]  Martin Hefford,et al.  Results of a telehealth-enabled chronic care management service to support people with long-term conditions at home , 2012, Journal of telemedicine and telecare.

[10]  Anne Holland,et al.  Telehealth reduces hospital admission rates in patients with COPD. , 2013, Journal of physiotherapy.

[11]  K. Traynor Dueling draft bills address tracking of pharmaceuticals. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  J. Bourbeau,et al.  Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.

[13]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[14]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[15]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[16]  M. Grillage,et al.  Long‐Term Oral Carbocisteine Therapy in Patients with Chronic Bronchitis. A Double Blind Trial with Placebo Control , 1985, The British journal of clinical practice.

[17]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[18]  S. Campbell,et al.  For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. , 1999, Archives of internal medicine.

[19]  J. Alonso,et al.  The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. , 2012, Archivos de bronconeumologia.

[20]  C. Crim,et al.  Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. , 2012, Clinical therapeutics.

[21]  N. Tzanakis,et al.  Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. , 2007, Respiratory medicine.

[22]  N. Zhong,et al.  Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.

[23]  W. Tam,et al.  Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD , 2011, Respirology.

[24]  R. Mehta,et al.  Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial , 2012, PloS one.

[25]  E. Toft,et al.  Cost-utility analysis of a telerehabilitation program: a case study of COPD patients. , 2012, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[26]  H. Bloomfield,et al.  Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. , 2010, American journal of respiratory and critical care medicine.

[27]  J. Lammers,et al.  Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial , 2011, Thorax.

[28]  F. Martinez,et al.  The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.

[29]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[30]  P. Poole,et al.  Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[31]  T. Seemungal,et al.  Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations , 2002, Thorax.

[32]  N. Zhong,et al.  Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.

[33]  Janita Pak-Chun Chau,et al.  A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease , 2012, Int. J. Medical Informatics.

[34]  K. Fong,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[35]  D. Postma,et al.  Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.

[36]  Meilan K. Han,et al.  Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Vestbo,et al.  Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study , 2002, Thorax.

[38]  R. Dahl,et al.  Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. , 2013, Respiratory medicine.

[39]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[40]  M. Cazzola,et al.  Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. , 2003, Respiratory medicine.

[41]  P. Chanez,et al.  Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .

[42]  S. Pocock,et al.  Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.

[43]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[44]  A. Buist,et al.  In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .

[45]  M. A. Martínez-García,et al.  Eficacia de un programa específico para pacientes con EPOC que presentan frecuentes agudizaciones , 2006 .

[46]  S. Rennard,et al.  Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.

[47]  Gordon H Guyatt,et al.  Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease , 1996, The Lancet.

[48]  J. Castro‐Rodriguez,et al.  Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. , 2012, Pulmonary pharmacology & therapeutics.

[49]  C. Trott,et al.  The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). , 1999, Australian and New Zealand journal of medicine.

[50]  C. Cates,et al.  Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[51]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[52]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[53]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[54]  T. Jørgensen,et al.  The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD) , 2008, The clinical respiratory journal.

[55]  M. Cazzola,et al.  The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.

[56]  B. Beghé,et al.  Inhaled corticosteroids in COPD: pros and cons. , 2013, Current drug targets.

[57]  D. Warm,et al.  Does Home Telemonitoring after Pulmonary Rehabilitation Reduce Healthcare Use in Optimized COPD?? A Pilot Randomized Trial , 2011, COPD.

[58]  G. Duvel The study group. , 1980 .

[59]  B. Smith,et al.  Long-acting beta2-agonists for chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.

[60]  D. Hui,et al.  Roflumilast in Asian patients with COPD: A randomized placebo‐controlled trial , 2011, Respirology.

[61]  B. Yawn,et al.  Inflammation in COPD: implications for management. , 2012, The American journal of medicine.

[62]  R. Murray,et al.  Smoking cessation in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.

[63]  M. Friedman A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. , 1996, The American journal of medicine.

[64]  Michael A. Kuskowski,et al.  Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. , 2000, American journal of respiratory and critical care medicine.

[65]  D. Halpin,et al.  A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[66]  V. Brusasco Reducing cholinergic constriction: the major reversible mechanism in COPD , 2006, European Respiratory Review.

[67]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[68]  F. Gallefoss The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. , 2004, Patient education and counseling.

[69]  R. Pauwels,et al.  Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. , 2004, Respiratory medicine.

[70]  R. Wootton Twenty years of telemedicine in chronic disease management – an evidence synthesis , 2012, Journal of telemedicine and telecare.

[71]  N. Gross,et al.  Inhalation by Nebulization of Albuterol-Ipratropium Combination (Dey Combination) Is Superior to Either Agent Alone in the Treatment of Chronic Obstructive Pulmonary Disease , 1998, Respiration.

[72]  M. Lainscak,et al.  Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. , 2012, Journal of the American Medical Directors Association.

[73]  S. Johnston,et al.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.

[74]  Reinier Akkermans,et al.  Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial , 2012, BMJ : British Medical Journal.

[75]  E. Bleecker,et al.  Results of a multicenter study of nebulized inhalant bronchodilator solutions. , 1996, The American journal of medicine.

[76]  Moon Fai Chan,et al.  Effects of nurse-initiated telephone follow-up on self-efficacy among patients with chronic obstructive pulmonary disease. , 2005, Journal of advanced nursing.

[77]  K. Traynor Fluticasone-vilanterol combination approved for COPD. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[78]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[79]  F. Martinez,et al.  Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. , 2013, Respiratory medicine.

[80]  Y. Lacasse,et al.  Pulmonary rehabilitation for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[81]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[82]  R. Wood‐Baker,et al.  Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations , 2006, Respirology.

[83]  G. Boman,et al.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. , 1983, European journal of respiratory diseases.

[84]  J. L. Alonso,et al.  The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. , 2012 .

[85]  P. Frith,et al.  Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[86]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[87]  D. Postma,et al.  Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. , 2009, Annals of internal medicine.

[88]  R. Mehta,et al.  Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study , 2013, International journal of chronic obstructive pulmonary disease.

[89]  Christopher B Cooper,et al.  Airflow obstruction and exercise. , 2009, Respiratory medicine.

[90]  P. Poole,et al.  Does early pulmonary rehabilitation reduce acute health‐care utilization in COPD patients admitted with an exacerbation? A randomized controlled study , 2009, Respirology.

[91]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[92]  H. Magnussen,et al.  Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. , 1995, The European respiratory journal.

[93]  J. Kleijnen,et al.  Smoking cessation interventions in COPD: a network meta-analysis of randomised trials , 2009, European Respiratory Journal.

[94]  J. Walters,et al.  Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. , 2010, The Cochrane database of systematic reviews.

[95]  A. Jarab,et al.  Impact of pharmaceutical care on health outcomes in patients with COPD , 2012, International Journal of Clinical Pharmacy.

[96]  P. Tarsia,et al.  Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. , 1997, Journal of chemotherapy.

[97]  Richard Casaburi,et al.  Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. , 2007, Chest.

[98]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[99]  J. Walters,et al.  Effects of telephone health mentoring in community-recruited chronic obstructive pulmonary disease on self-management capacity, quality of life and psychological morbidity: a randomised controlled trial , 2013, BMJ Open.

[100]  E. Seydel,et al.  Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[101]  W. Dejsomritrutai,et al.  Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. , 2004, Chest.

[102]  L. Allegra,et al.  Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. , 1990, Respiration; international review of thoracic diseases.

[103]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[104]  C. Sanguinetti,et al.  N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD , 1999, Respiration.

[105]  M. Polkey,et al.  Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study , 2004, BMJ : British Medical Journal.

[106]  C. Vogelmeier,et al.  Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study , 2009, Respiratory research.

[107]  Mark Petticrew,et al.  When are complex interventions 'complex'? When are simple interventions 'simple'? , 2011, European journal of public health.

[108]  Martin Knapp,et al.  Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial , 2013, BMJ.

[109]  J. Bourbeau,et al.  The burden of COPD in Canada: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[110]  C. Grassi,et al.  A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis , 1976, European Journal of Clinical Pharmacology.

[111]  Peter J. Barnes,et al.  Inhaled Corticosteroids in COPD: A Controversy , 2010, Respiration.

[112]  P. B. Koff,et al.  Proactive integrated care improves quality of life in patients with COPD , 2009, European Respiratory Journal.

[113]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[114]  M. Decramer,et al.  Integrated care prevents hospitalisations for exacerbations in COPD patients , 2006, European Respiratory Journal.

[115]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[116]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[117]  F. Weaver,et al.  Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma , 2007, Journal of General Internal Medicine.

[118]  P. Calverley Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.

[119]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[120]  S. Biswal,et al.  Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress , 2011, Biochemical and biophysical research communications.

[121]  F. Maltais,et al.  Counting, analysing and reporting exacerbations of COPD in randomised controlled trials , 2007, Thorax.

[122]  C. Whitney,et al.  Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). , 2010, MMWR. Morbidity and mortality weekly report.

[123]  P. Barnes New Therapies for Chronic Obstructive Pulmonary Disease , 2010, Medical Principles and Practice.

[124]  P. Poole,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[125]  Alison Lesley Weightman,et al.  Grading evidence and recommendationsfor public health interventions: developing and pilotinga framework , 2005 .

[126]  F. Maltais,et al.  Self-management reduces both short- and long-term hospitalisation in COPD , 2005, European Respiratory Journal.

[127]  A. Church,et al.  Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.

[128]  J. B. Rasmussen,et al.  Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. , 1988, The European respiratory journal.

[129]  W. MacNee,et al.  Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease , 2010, Respiration.

[130]  L. Kuramoto,et al.  The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. , 2008, Respiratory medicine.

[131]  J. Cramer,et al.  Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[132]  R. Zuwallack,et al.  Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. , 1996, The American journal of medicine.

[133]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[134]  Joseph Ornelas,et al.  Methodologies for the development of CHEST guidelines and expert panel reports. , 2014, Chest.

[135]  M. Thabane Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. , 2012, Ontario health technology assessment series.

[136]  G. Parr,et al.  Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. , 1987, British journal of diseases of the chest.

[137]  J. Escarrabill,et al.  Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. , 2001, Chest.

[138]  J. Walters,et al.  Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. , 2010, The Cochrane database of systematic reviews.

[139]  Robert J Pierce,et al.  Pilot study of remote telemonitoring in COPD. , 2012, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[140]  Jiaquan Xu,et al.  Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[141]  Michael K Gould,et al.  Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. , 2006, Archives of neurology.

[142]  M. Cazzola,et al.  The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.

[143]  E. Walters,et al.  Self-management education for patients with chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[144]  V. Debari,et al.  Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study , 2008, International journal of clinical practice.

[145]  M. Decramer,et al.  Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.

[146]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[147]  M. Cazzola,et al.  Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease , 2007, Expert opinion on therapeutic targets.

[148]  Melanie Irvin-sellers,et al.  Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[149]  Ramon Gisbert,et al.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.

[150]  I. Stiell,et al.  Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.

[151]  H. Rea,et al.  A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease , 2004, Internal medicine journal.

[152]  A. Boxall,et al.  Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. , 2005, Journal of cardiopulmonary rehabilitation.

[153]  E. Kerwin,et al.  A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. , 2013, Respiratory medicine.

[154]  E. Wouters Economic analysis of the Confronting COPD survey: an overview of results. , 2003, Respiratory medicine.

[155]  S. Lam,et al.  Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[156]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[157]  N. Chavannes,et al.  Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. , 2009, Respiratory medicine.

[158]  D. Sin,et al.  Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis , 2012, International journal of chronic obstructive pulmonary disease.

[159]  S. Straus,et al.  Lost in knowledge translation: Time for a map? , 2006, The Journal of continuing education in the health professions.

[160]  P. Enright,et al.  Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.

[161]  S. Spencer,et al.  Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[162]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[163]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[164]  P. Barnes Development of new drugs for COPD. , 2013, Current medicinal chemistry.

[165]  R. Zuwallack,et al.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.

[166]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[167]  Harlan M. Krumholz,et al.  A Taxonomy for Disease Management: A Scientific Statement From the American Heart Association Disease Management Taxonomy Writing Group , 2006, Circulation.

[168]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[169]  E H Wagner,et al.  Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.

[170]  G. Marks,et al.  Primary care Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease , 2022 .

[171]  P. Van der valk,et al.  Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease , 2004, Infection and Immunity.

[172]  A. Aggarwal,et al.  Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. , 2010, Chest.

[173]  P. Lange,et al.  Long‐term Effects of 1‐Year Maintenance Training on Physical Functioning and Health Status in Patients With COPD: A Randomized Controlled Study , 2010, Journal of cardiopulmonary rehabilitation and prevention.

[174]  P. Poole,et al.  Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[175]  M. Martínez-García,et al.  [Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations]. , 2006, Archivos de bronconeumologia.

[176]  M. Cazzola,et al.  Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease , 2013, Expert opinion on pharmacotherapy.

[177]  G. Feldman,et al.  28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. , 2012, Pulmonary pharmacology & therapeutics.

[178]  P. Jones,et al.  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.

[179]  P. Wludyka,et al.  A randomized trial of two types of nurse-assisted home care for patients with COPD. , 2005, Chest.

[180]  T. Evald,et al.  Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. , 1994, Respiratory medicine.

[181]  J. Lötvall,et al.  Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial , 2012, BMJ Open.

[182]  L. W. Jacobs,et al.  THE IN VITRO REDUCTION IN VISCOSITY OF HUMAN TRACHEOBRONCHIAL SECRETIONS BY ACETYLCYSTEINE. , 2015, The American review of respiratory disease.

[183]  Claudio Pedone,et al.  Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial , 2013, BMC Health Services Research.

[184]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[185]  J. Izquierdo,et al.  The burden of COPD in Spain: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[186]  N. Gross,et al.  Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. , 2008, Respiratory medicine.

[187]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[188]  Egon Toft,et al.  Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients , 2012, Journal of telemedicine and telecare.

[189]  M. Puhan,et al.  Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2016, The Cochrane database of systematic reviews.

[190]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[191]  J. V. van Noord,et al.  24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. , 2011, Pulmonary pharmacology & therapeutics.

[192]  D. O’Donnell,et al.  Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[193]  D. Brooks,et al.  Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline. , 2010, Canadian respiratory journal.

[194]  A. Buist,et al.  Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. , 1999, The American journal of medicine.

[195]  G. Colice Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. , 1996, The American journal of medicine.

[196]  D. Niewoehner,et al.  Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.

[197]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[198]  M. Cazzola,et al.  Emerging drugs for chronic obstructive pulmonary disease , 2012, Expert opinion on emerging drugs.

[199]  P. Bottrighi,et al.  The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. , 2004, Drugs under experimental and clinical research.

[200]  P. Barnes Glucocorticosteroids: current and future directions , 2011, British journal of pharmacology.

[201]  P. Barnes,et al.  Role of HDAC2 in the pathophysiology of COPD. , 2009, Annual review of physiology.

[202]  N. Chavannes,et al.  Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[203]  J. Hendy,et al.  Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial , 2012, BMJ : British Medical Journal.

[204]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[205]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[206]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[207]  S. Spencer,et al.  Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[208]  M. Dueholm,et al.  N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. , 1992, Respiratory medicine.

[209]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[210]  M. Cazzola,et al.  Emerging anti-inflammatory strategies for COPD , 2012, European Respiratory Journal.

[211]  P. Casarosa,et al.  Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol , 2011, Journal of Pharmacology and Experimental Therapeutics.

[212]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[213]  B. Smith,et al.  Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[214]  T. Seemungal,et al.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[215]  D. V. Hoff,et al.  Tiotropium and the Risk of Death in COPD , 2014 .

[216]  E. Bateman,et al.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.

[217]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[218]  A. Sharafkhaneh,et al.  Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.

[219]  N. Wig,et al.  Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[220]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[221]  K. Fagerström,et al.  Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy , 2006, European Respiratory Journal.

[222]  Silvia Jiménez-Fernández,et al.  Telemedicine Experience for Chronic Care in COPD , 2006, IEEE Transactions on Information Technology in Biomedicine.

[223]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[224]  Jim Basilakis,et al.  Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. , 2010, Studies in health technology and informatics.

[225]  W. Banya,et al.  Statins and outcome after hospitalization for COPD exacerbation: a prospective study. , 2011, Pulmonary pharmacology & therapeutics.

[226]  R. Casaburi,et al.  Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. , 2011, Respiratory medicine.

[227]  B. Grant,et al.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.

[228]  S. Inglis,et al.  Non‐pharmacological management interventions for COPD: an overview of Cochrane systematic reviews , 2013 .

[229]  Y. Lacasse,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. , 2008, Canadian respiratory journal.

[230]  M. Miravitlles,et al.  Clinical Outcomes and Cost Analysis of Exacerbations in Chronic Obstructive Pulmonary Disease , 2013, Lung.

[231]  D. Hui,et al.  Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis , 2013, PloS one.

[232]  H. Magnussen,et al.  Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. , 2000, Respiratory medicine.

[233]  A. Sheikh,et al.  The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. , 2009, Primary Care Respiratory Journal.

[234]  J. Crowley,et al.  Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.

[235]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[236]  D. Malone,et al.  Statin use and risk of COPD exacerbation requiring hospitalization. , 2013, The American journal of medicine.

[237]  F. Jódar-Sánchez,et al.  Implementation of a Telehealth Programme for Patients with Severe Chronic Obstructive Pulmonary Disease Treated with Long-Term Oxygen Therapy , 2013, Journal of telemedicine and telecare.

[238]  J. McElnay,et al.  Clinical pharmacy-led disease and medicine management programme for patients with COPD. , 2009, British journal of clinical pharmacology.

[239]  T. Iwanaga,et al.  Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. , 2008, Vaccine.

[240]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[241]  Tzeng-Ji Chen,et al.  Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. , 2011, Clinical therapeutics.

[242]  M. Hyland,et al.  Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire , 2011, Geriatrics & gerontology international.

[243]  J. Hallas,et al.  Nurse tele‐consultations with discharged COPD patients reduce early readmissions – an interventional study , 2011, The clinical respiratory journal.

[244]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[245]  Aziz Sheikh,et al.  Telehealthcare for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[246]  P. Jones,et al.  Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. , 2011, Respiratory medicine.

[247]  F. Blackstock,et al.  Disease-specific health education for COPD: a systematic review of changes in health outcomes. , 2006, Health education research.

[248]  L. Raiteri,et al.  Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[249]  R. Wood‐Baker,et al.  Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[250]  C. Dowson,et al.  Self‐management plans in the primary care of patients with chronic obstructive pulmonary disease , 2006, Respirology.

[251]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness: the chronic care model, Part 2. , 2002, JAMA.

[252]  S. Scalvini,et al.  Tele-assistance in chronic respiratory failure patients: a randomised clinical trial , 2008, European Respiratory Journal.

[253]  Elizabeth M. Borycki,et al.  Reduction of Hospital Utilization in Patients With Chronic Obstructive Pulmonary Disease: A Disease-Specific Self-management Intervention , 2003 .

[254]  E. Silverman,et al.  Predictors of survival in severe, early onset COPD. , 2004, Chest.

[255]  R. Jiménez-García,et al.  Inappropriate Overuse of Inhaled Corticosteroids for COPD Patients: Impact on Health Costs and Health Status , 2011, Lung.

[256]  Grant D. Huang,et al.  A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations , 2012, Annals of Internal Medicine.

[257]  M. Miravitlles,et al.  Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. , 2001, Chest.

[258]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[259]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[260]  M. Polkey,et al.  Outpatient pulmonary rehabilitation following acute exacerbations of COPD , 2010, Thorax.

[261]  T. Lasserson,et al.  Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[262]  L. Merz,et al.  P154 Development of the Documentation And Appraisal Review Tool (Dart) For Systematic Reviews , 2013 .

[263]  A. Monto Influenza: quantifying morbidity and mortality. , 1987, The American journal of medicine.

[264]  M. Cazzola,et al.  Emerging inhaled bronchodilators: an update , 2009, European Respiratory Journal.

[265]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[266]  E. Bleecker,et al.  Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. , 1986, The American journal of medicine.

[267]  Thierry Troosters,et al.  An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. , 2013, American journal of respiratory and critical care medicine.

[268]  T. Ten Have,et al.  Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. , 2012, The Gerontologist.

[269]  N. Murphy,et al.  Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. , 2005, Respiratory medicine.

[270]  C. Taube,et al.  Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. , 2011, Pulmonary pharmacology & therapeutics.

[271]  D. Au,et al.  The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations , 2009, Journal of General Internal Medicine.

[272]  J. DiNicolantonio,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[273]  L. Fabbri,et al.  Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients , 2010, COPD.

[274]  R. Zuwallack,et al.  An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. , 2012, Proceedings of the American Thoracic Society.

[275]  C. Howells,et al.  Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. , 1961, Lancet.

[276]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[277]  M. Esteva,et al.  Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial , 2013, BMC Family Practice.

[278]  M. Cazzola,et al.  β2‐adrenoceptor agonists: current and future direction , 2011, British journal of pharmacology.

[279]  G. Paré,et al.  Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: A randomized controlled trial , 2013 .

[280]  A. Buist,et al.  Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. , 1997, Chest.

[281]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[282]  J. Steurer,et al.  Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2009, The Cochrane database of systematic reviews.

[283]  M. Polkey,et al.  Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study , 2004, BMJ : British Medical Journal.

[284]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness. , 2002, JAMA.